Diplomat’s Amy Clarke Elected as President of Immunoglobulin National Society
FLINT, Mich. – March 8, 2016 – The nation’s largest independent specialty pharmacy is proud to announce that Diplomat’s Amy Clarke has been named president of the Immunoglobulin National Society.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its Specialty Infusion Services Group Program Manager, Amy Clarke, RN, IgCN, has been elected as the president of the Immunoglobulin National Society (IgNS) for the 2016–2018 term.
IgNS is a professional organization dedicated to nurses and pharmacists in education, management, practice and research in fields of immunoglobulin (IG) therapy. IgNS has been at the forefront of advancing the IG nursing field.
Prior to joining Diplomat in 2009, Clarke was an infusion nurse at BioRx, where she provided practical and instructional support for hemophilia and IVIG, working closely with physicians’ offices, clinics and nursing agencies to provide teaching and therapy understanding to both clinicians and patients nationally. Previously, she served as a clinical consultant at Quality Care, and director of nursing at Option Care and Chartwell Care Givers, Inc.
“Amy brings a wealth of clinical expertise in IG therapy,” said Gary Kadlec president of Diplomat. “With a strong background in leadership throughout her career, she will be a tremendous addition to the board.”
Clarke is a registered nurse and has been in the home infusion space since 1994. As a director of nursing for the Chicago locations of Chartwell Diversified Services and Option Care’s Home Infusion Therapy Pharmacies, Clarke provided clinical education on infusion therapy and specialty medications to nursing staff, pharmacists, physicians and social workers.
To learn more about Diplomat and its specialty infusion program, click here.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
@DiplomatRxWe are #hiring sales consultants for both NYC and Oakland, California! Come check it out. https://t.co/GDqMaItrsZ5 days ago
@gchabitatRT @gchabitat: Do you have what it takes to be a Habitat Olympian? Join us at @DiplomatRx on 5/5 to find out! https://t.co/5eq5y94hv36 days ago
@DiplomatRxDiplomat Will Dispense ZEJULA™ to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer… https://t.co/MnQRQdLufl1 week ago
@DiplomatRxFar more than an adventure, their trip was dedicated to assisting people living with #hemophilia… https://t.co/kngmnkvjvU2 weeks ago
@DiplomatRxDiplomat to Release First Quarter 2017 Operating Results and Host Conference Call on Monday, May 8, 2017… https://t.co/h6vJR7823O2 weeks ago